Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics
Pacira BioSciences, Inc. (PCRX)
Today's Latest Price: $60.12 USD
Updated Sep 30 6:55pm
Add PCRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
PCRX Stock Summary
- With a one year PEG ratio of 533.05, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.43% of US stocks.
- The price/operating cash flow metric for Pacira BioSciences Inc is higher than 95.38% of stocks in our set with a positive cash flow.
- With a price/sales ratio of 6.29, Pacira BioSciences Inc has a higher such ratio than 80.38% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Pacira BioSciences Inc are YELP, AYX, GORO, KALA, and VIVE.
- PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.
PCRX Stock Price Chart Technical Analysis Charts
PCRX Price/Volume Stats
| Current price | $60.12 | 52-week high | $64.44 |
| Prev. close | $59.39 | 52-week low | $27.46 |
| Day low | $58.67 | Volume | 461,500 |
| Day high | $60.87 | Avg. volume | 661,932 |
| 50-day MA | $58.86 | Dividend yield | N/A |
| 200-day MA | $47.15 | Market Cap | 2.57B |
Pacira BioSciences, Inc. (PCRX) Company Bio
Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.
PCRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $60.12 | $7.01 | -88% |
Below please find a table outlining a discounted cash flow forecast for PCRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacira BioSciences Inc ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacira BioSciences Inc ended up being:
- 87% of the company's capital comes from equity, which is greater than 71.6% of stocks in our cash flow based forecasting set.
- The weighted average cost of capital for the company is 9. This value is greater than 73.04% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -89% |
| 1% | -88% |
| 2% | -88% |
| 3% | -88% |
| 4% | -88% |
| 5% | -88% |
Want more companies with a valuation profile/forecast similar to that of Pacira BioSciences Inc? See LGND, BLFS, LMNX, STAA, and RGEN.
Loading social stream, please wait...